Business Context and Reporting Period
This Form 8-K is a current report filed by Synaptogenix, Inc. (not TAO Synergies Inc.) on June 16, 2023. The registrant is a Delaware corporation and an emerging growth company, with its principal executive offices in New York, New York. The report primarily addresses executive compensation arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and employment agreements rather than financial performance data.
Material Changes
The material change reported is the amendment of the employment agreement for the Chief Executive Officer:
- Executive: Alan J. Tuchman, M.D., CEO.
- Action: Execution of a Second Amendment to the Offer Letter on June 16, 2023.
- Term Extension: The employment term was extended through June 7, 2024.
- Renewal Terms: The agreement includes automatic monthly renewals thereafter unless terminated earlier in accordance with the amendment's terms.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies are detailed in this report other than the standard reference to the full text of the employment amendment for complete terms.
Investor Verification Checklist
- Verify the full text of the Second Amendment (Exhibit 10.1) to understand specific compensation details and termination clauses.
- Confirm the company's current status as an emerging growth company and its implications for financial reporting.
- Review recent 10-K or 10-Q filings for actual financial metrics, as this 8-K does not contain them.
- Note the discrepancy in the request metadata regarding the company name; the filing is for Synaptogenix, Inc. (SNPX), not TAO Synergies Inc.